

Supplement Tables

Supplement Table 1: Assessment of company data sharing procedures

Supplement Table 2: Assessment of registration, results reporting, and publication practices for trials supporting FDA approval of novel drugs and biologics approved by the FDA in 2016 and 2017

Supplement Table 3: Assessment of FDAAA compliance for applicable trials supporting approval of each product

Supplement Table 4: Company and product characteristics

Supplement Table 1: Assessment of company data sharing procedures

Company	% of covered trials registered (proportion)	Before 30-day amendment window					After 30-day amendment window				
		Policy provides access to analysis ready dataset & CSR	Policy explains how data may be requested	Company publicly reports No, and outcome of data requests	Policy specifies data will be shared by deadline	Overall data sharing score	Policy provides access to analysis ready dataset & CSR	Policy explains how data may be requested	Company publicly reports No, and outcome of data requests	Policy specifies data will be shared by deadline	Overall data sharing score
AbbVie	100 (13/13)	100	100	100	100	100	100	100	100	100	100
Aerie	100 (7/7)	0	0	0	0	20	0	0	0	0	20
Amgen	100 (15/15)	100	100	100	100	100	100	100	100	100	100
AstraZeneca	100 (13/13)	100	100	100	100	100	100	100	100	100	100
Bausch Health	100 (7/7)	100	100	0	100	80	100	100	0	100	80
Bayer	100 (9/9)	100	100	100	100	100	100	100	100	100	100
Biogen	100 (14/14)	100	100	100	0	80	100	100	100	0	80
BioMarin	100 (3/3)	0	100	0	0	40	0	100	0	0	40
Celgene	100 (1/1)	100	100	100	0	80	100	100	100	0	80
Chemo Research	33 (1/3)	0	0	0	0	7	0	0	0	0	7
Eli Lilly	100 (13/13)	100	100	100	0	80	100	100	100	0	80
Ferrer	100 (2/2)	0	0	0	0	20	0	0	0	0	20
Gilead	100 (19/19)	100	100	0	100	80	100	100	0	100	80
Johnson & Johnson/Janssen	100 (7/7)	100	100	100	100	100	100	100	100	100	100
La Jolla	50 (1/2)	0	0	0	0	10	0	0	0	0	10
Lexicon	100 (5/5)	0	0	0	0	20	0	0	0	0	20
Lupin	100 (3/3)	0	0	0	0	20	0	0	0	0	20
Melinta Therapeutics	100 (4/4)	0	0	0	0	20	0	0	0	0	20
Merck KGaA/EMD Serono ^a	100 (1/1)	100	100	100	0	80	100	100	100	100	100
Merck Sharp & Dohme	91 (31/33)	100	100	100	100	98	100	100	100	100	98
Mitsubishi Tanabe	80 (4/5)	0	0	0	0	16	0	0	0	0	16
Neurocrine Biosciences	100 (6/6)	0	0	0	0	20	0	0	0	0	20
Novartis	100 (11/11)	100	100	100	100	100	100	100	100	100	100
Novo Nordisk	100 (13/13)	100	100	100	100	100	100	100	100	100	100
Pfizer	88 (7/8)	100	100	100	0	80	100	100	100	0	80
Portola	100 (4/4)	0	0	0	0	20	0	0	0	0	20

PTC Therapeutics	40 (2/5)	0	0	0	0	8	0	0	0	0	8
Puma Biotechnology	100 (5/5)	0	0	0	0	20	0	0	0	0	20
Radius ^a	100 (4/4)	0	0	0	0	20	100	100	0	100	80
Regeneron	100 (8/8)	100	100	100	0	80	100	100	100	0	80
The Medicines Company/Rempe x	100 (2/2)	0	0	0	0	20	0	0	0	0	20
Roche/Genentech	100 (12/12)	100	100	100	100	100	100	100	100	100	100
Sanofi	95 (35/37)	100	100	100	100	99	100	100	100	100	99
Shionogi	71 (5/7)	0	0	0	0	14	0	0	0	0	14
Shire ^a	100 (8/8)	100	100	0	0	60	100	100	100	100	100
Synergy	100 (5/5)	0	0	0	0	20	0	0	0	0	20
Takeda ^a	100 (3/3)	100	100	100	0	80	100	100	100	100	100
Tesaro	100 (3/3)	0	0	0	0	20	0	0	0	0	20
Teva	100 (4/4)	100	100	0	0	60	100	100	0	0	60
Ultragenyx	100 (2/2)	100	100	0	0	60	100	100	0	0	60
US Worldmeds	79 (11/14)	0	0	0	0	16	0	0	0	0	16
Valeant	100 (4/4)	0	0	0	0	20	0	0	0	0	20
Median [IQR]	100 [100-100]					60 [20-80]					69 [20-100]
Percentage of Companies fully meeting measure	79 (33/42)	52 (22/42)	55 (23/42)	40 (17/42)	29 (12/42)	19 (8/42)	55 (23/42)	57 (24/42)	43 (18/42)	38 (16/42)	26 (11/42)

^a Denotes company improved data sharing policy during 30-day amendment window.

Supplement Table 2: Assessment of registration, results reporting, and publication practices for trials supporting FDA approval of novel drugs and biologics approved by the FDA in 2016 and 2017

Company	Product	All trials sample				Patient trials sample			
		% Registered	% Reported	% Published	% Publicly available (reported or published)	% Registered	% Reported	% Published	% Publicly available (reported or published)
AbbVie	Mavyret	23 (10/43)	23 (10/43)	35 (15/43)	35 (15/43)	100 (10/10)	100 (10/10)	100 (10/10)	100 (10/10)
	Venclexta	71 (10/14)	0 (0/6)	67 (4/6)	67 (4/6)	100 (7/7)	NA	NA	NA
Aerie	Rhopressa	90 (9/10)	78 (7/9)	56 (5/9)	100 (9/9)	100 (7/7)	100 (7/7)	43 (3/7)	100 (7/7)
Amgen	Amjevita	80 (4/5)	80 (4/5)	40 (2/5)	80 (4/5)	100 (3/3)	100 (3/3)	33 (1/3)	100 (3/3)
	Parsabiv	100 (12/12)	100 (12/12)	75 (9/12)	100 (12/12)	100 (10/10)	100 (10/10)	70 (7/10)	100 (10/10)
AstraZeneca	Calquence	53 (8/15)	0 (0/8)	13 (1/8)	13 (1/8)	100 (2/2)	0 (0/1)	100 (1/1)	100 (1/1)
	Fasenra	100 (12/12)	55 (6/11)	82 (9/11)	82 (9/11)	100 (12/12)	55 (6/11)	82 (9/11)	82 (9/11)
	Imfinzi	100 (3/3)	100 (1/1)	100 (1/1)	100 (1/1)	100 (1/1)	NA	NA	NA
Bausch Health	Vyzulta	80 (8/10)	50 (5/10)	60 (6/10)	60 (6/10)	100 (7/7)	71 (5/7)	71 (5/7)	71 (5/7)
Bayer	Aliqopa	100 (12/12)	83 (5/6)	83 (5/6)	100 (6/6)	100 (8/8)	100 (3/3)	67 (2/3)	100 (3/3)
	Kovaltry	100 (3/3)	100 (2/2)	100 (2/2)	100 (2/2)	100 (3/3)	100 (2/2)	100 (2/2)	100 (2/2)
Biogen	Spinraza	100 (10/10)	100 (4/4)	75 (3/4)	100 (4/4)	100 (10/10)	100 (4/4)	75 (3/4)	100 (4/4)
	Zinbryta	67 (8/12)	30 (3/10)	90 (9/10)	90 (9/10)	100 (7/7)	60 (3/5)	100 (5/5)	100 (5/5)
BioMarin	Brineura	50 (3/6)	0 (0/1)	0 (0/1)	0 (0/1)	100 (3/3)	0 (0/1)	0 (0/1)	0 (0/1)
Celgene	Idhifa	80 (4/5)	0 (0/1)	0 (0/1)	0 (0/1)	100 (1/1)	NA	NA	NA
Chemo Research	Benznidazole	14 (5/35)	0 (0/31)	74 (23/31)	74 (23/31)	50 (2/4)	0 (0/4)	75 (3/4)	75 (3/4)
Eli Lilly	Lartruvo	100 (11/11)	78 (7/9)	56 (5/9)	89 (8/9)	100 (7/7)	60 (3/5)	80 (4/5)	80 (4/5)
	Taltz	83 (10/12)	83 (10/12)	83 (10/12)	100 (12/12)	86 (6/7)	86 (6/7)	100 (7/7)	100 (7/7)
	Verzenio	100 (20/20)	88 (14/16)	38 (6/16)	100 (16/16)	100 (3/3)	100 (3/3)	100 (3/3)	100 (3/3)
Ferrer	Xepi	18 (3/17)	12 (2/17)	35 (6/17)	35 (6/17)	67 (2/3)	67 (2/3)	67 (2/3)	100 (3/3)
Gilead	Epclusa	46 (17/37)	21 (7/33)	24 (8/33)	24 (8/33)	100 (12/12)	70 (7/10)	80 (8/10)	80 (8/10)
	Vosevi	62 (13/21)	40 (8/20)	45 (9/20)	45 (9/20)	100 (10/10)	89 (8/9)	100 (9/9)	100 (9/9)
Johnson & Johnson/Janssen	Tremfya	100 (13/13)	77 (10/13)	54 (7/13)	85 (11/13)	100 (8/8)	88 (7/8)	75 (6/8)	100 (8/8)
La Jolla	Giapreza	33 (3/9)	11 (1/9)	33 (3/9)	33 (3/9)	67 (2/3)	33 (1/3)	67 (2/3)	67 (2/3)
Lexicon	Xermelo	86 (12/14)	38 (5/13)	23 (3/13)	38 (5/13)	100 (5/5)	100 (4/4)	75 (3/4)	100 (4/4)
Lupin	Solosec	38 (3/8)	13 (1/8)	88 (7/8)	88 (7/8)	100 (3/3)	33 (1/3)	100 (3/3)	100 (3/3)
Melinta Therapeutics	Baxdela	18 (6/33)	12 (4/33)	36 (12/33)	39 (13/33)	100 (4/4)	100 (4/4)	75 (3/4)	100 (4/4)
Merck KGaA/EMD Serono	Bavencio	75 (3/4)	100 (1/1)	0 (0/1)	100 (1/1)	100 (1/1)	NA	NA	NA
Merck Sharp & Dohme	Prevymis	7 (2/27)	7 (2/27)	37 (10/27)	37 (10/27)	67 (2/3)	67 (2/3)	100 (3/3)	100 (3/3)
	Steglatro	50 (18/36)	37 (13/35)	46 (16/35)	54 (19/35)	100 (11/11)	100 (10/10)	90 (9/10)	100 (10/10)
	Zepatier	33 (21/63)	24 (15/62)	16 (10/62)	27 (17/62)	100 (18/18)	82 (14/17)	59 (10/17)	94 (16/17)
	Zinplava	33 (3/9)	22 (2/9)	33 (3/9)	33 (3/9)	75 (3/4)	50 (2/4)	75 (3/4)	75 (3/4)

Mitsubishi Tanabe	Radicava	27 (4/15)	27 (4/15)	27 (4/15)	27 (4/15)	80 (4/5)	80 (4/5)	80 (4/5)	80 (4/5)
Neurocrine Biosciences	Ingrezza	50 (8/16)	25 (4/16)	38 (6/16)	38 (6/16)	100 (6/6)	67 (4/6)	100 (6/6)	100 (6/6)
Novartis	Erelzi	33 (2/6)	20 (1/5)	60 (3/5)	60 (3/5)	100 (2/2)	100 (1/1)	100 (1/1)	100 (1/1)
	Kisqali	71 (12/17)	30 (3/10)	40 (4/10)	40 (4/10)	100 (5/5)	100 (1/1)	100 (1/1)	100 (1/1)
	Rydapt	36 (8/22)	32 (6/19)	58 (11/19)	63 (12/19)	100 (6/6)	100 (5/5)	100 (5/5)	100 (5/5)
Novo Nordisk	Macrilen	38 (3/8)	29 (2/7)	57 (4/7)	57 (4/7)	100 (2/2)	100 (2/2)	100 (2/2)	100 (2/2)
	Ozempic	100 (30/30)	83 (24/29)	69 (20/29)	90 (26/29)	100 (13/13)	92 (12/13)	85 (11/13)	100 (13/13)
Pfizer/Wyeth	Besponsa	100 (11/11)	91 (10/11)	91 (10/11)	100 (11/11)	100 (2/2)	100 (2/2)	100 (2/2)	100 (2/2)
Pfizer/Anacor	Eucrisa	52 (12/23)	39 (9/23)	30 (7/23)	48 (11/23)	83 (5/6)	83 (5/6)	83 (5/6)	83 (5/6)
Portola	Bevyxxa	35 (7/20)	20 (4/20)	20 (4/20)	25 (5/20)	100 (4/4)	100 (4/4)	75 (3/4)	100 (4/4)
PTC Therapeutics	Emflaza	57 (8/14)	0 (0/11)	9 (1/11)	9 (1/11)	57 (4/7)	0 (0/4)	25 (1/4)	25 (1/4)
Puma Biotechnology	Nerlynx	100 (18/18)	60 (9/15)	67 (10/15)	80 (12/15)	100 (7/7)	100 (6/6)	83 (5/6)	100 (6/6)
Radius	Tymlos	27 (4/15)	20 (3/15)	20 (3/15)	27 (4/15)	100 (4/4)	75 (3/4)	75 (3/4)	100 (4/4)
Regeneron	Dupixent	89 (16/18)	35 (6/17)	53 (9/17)	53 (9/17)	100 (11/11)	60 (6/10)	80 (8/10)	80 (8/10)
The Medicines Company/Rempex	Vabomere	100 (7/7)	17 (1/6)	67 (4/6)	67 (4/6)	100 (2/2)	50 (1/2)	50 (1/2)	50 (1/2)
Roche/Genentech	Hemlibra	80 (4/5)	33 (1/3)	67 (2/3)	67 (2/3)	100 (3/3)	50 (1/2)	100 (2/2)	100 (2/2)
	Ocrevus	87 (13/15)	27 (4/15)	73 (11/15)	73 (11/15)	100 (4/4)	100 (4/4)	100 (4/4)	100 (4/4)
	Tecentriq	100 (8/8)	83 (5/6)	67 (4/6)	100 (6/6)	100 (6/6)	100 (5/5)	60 (3/5)	100 (5/5)
Sanofi	Adlyxin	50 (28/56)	49 (27/55)	47 (26/55)	52 (29/55)	93 (26/28)	93 (26/28)	86 (24/28)	96 (27/28)
	Kevzara	88 (21/24)	55 (12/22)	27 (6/22)	59 (13/22)	100 (13/13)	83 (10/12)	33 (4/12)	83 (10/12)
Shionogi	Symproic	22 (5/23)	100 (23/23)	30 (7/23)	100 (23/23)	71 (5/7)	100 (7/7)	57 (4/7)	100 (7/7)
Shire/Baxalta	Cuvitru	100 (3/3)	100 (3/3)	100 (3/3)	100 (3/3)	100 (3/3)	100 (3/3)	100 (3/3)	100 (3/3)
Shire	Xiidra	100 (7/7)	86 (6/7)	86 (6/7)	100 (7/7)	100 (5/5)	100 (5/5)	100 (5/5)	100 (5/5)
Synergy	Trulance	75 (6/8)	0 (0/8)	13 (1/8)	13 (1/8)	100 (5/5)	0 (0/5)	20 (1/5)	20 (1/5)
Takeda/Ariad	Alunbrig	60 (3/5)	50 (2/4)	50 (2/4)	50 (2/4)	100 (3/3)	100 (2/2)	100 (2/2)	100 (2/2)
Tesaro	Zejula	100 (4/4)	0 (0/3)	100 (3/3)	100 (3/3)	100 (3/3)	0 (0/2)	100 (2/2)	100 (2/2)
Teva	Austedo	40 (4/10)	13 (1/8)	25 (2/8)	25 (2/8)	100 (4/4)	50 (1/2)	100 (2/2)	100 (2/2)
Ultragenyx	Mepsevii	78 (7/9)	100 (2/2)	50 (1/2)	100 (2/2)	100 (6/6)	100 (2/2)	50 (1/2)	100 (2/2)
US Worldmeds	Xadago	37 (14/38)	16 (6/38)	29 (11/38)	34 (13/38)	79 (11/14)	36 (5/14)	50 (7/14)	50 (7/14)
Valeant	Siliq	81 (17/21)	74 (14/19)	58 (11/19)	84 (16/19)	100 (7/7)	67 (4/6)	67 (5/6)	67 (5/6)
Median [IQR]		73 [38-100]	34 [18-80]	50 [30-67]	62 [36-98]	100 [100]	87 [60-100]	81 [68-100]	100 [83-100]
Percentage fully meeting measure		27 (17/62)	13 (8/62)	6 (4/62)	26 (16/62)	81 (50/62)	43 (25/58)	38 (22/58)	6 (39/58)

Supplement Table 3: Assessment of FDAAA compliance for applicable trials supporting approval of each product

Company	Product	% Timely registered	% Timely reported	% FDAAA compliant
AbbVie	Mavyret	100 (10/10)	100 (10/10)	100 (10/10)
	Venclexta	NA	NA	NA
Aerie	Rhopressa	100 (7/7)	57 (4/7)	57 (4/7)
Amgen	Amjevita	100 (3/3)	100 (3/3)	100 (3/3)
	Parsabiv	100 (9/9)	100 (9/9)	100 (9/9)
AstraZeneca	Calquence	100 (1/1)	0 (0/1)	0 (0/1)
	Fasenra	100 (9/9)	78 (7/9)	78 (7/9)
	Imfinzi	NA	NA	NA
Bausch Health	Vyzulta	100 (6/6)	0 (0/6)	0 (0/6)
Bayer	Aliqopa	100 (2/2)	100 (2/2)	100 (1/1)
	Kovaltry	100 (2/2)	100 (2/2)	100 (2/2)
Biogen	Spinraza	100 (2/2)	100 (2/2)	100 (2/2)
	Zinbryta	100 (2/2)	100 (2/2)	100 (2/2)
BioMarin	Brineura	100 (1/1)	0 (0/1)	0 (0/1)
Celgene	Idhifa	NA	NA	NA
Chemo Research	Benznidazole	NA	NA	NA
Eli Lilly	Lartruvo	100 (2/2)	100 (2/2)	100 (2/2)
	Taltz	100 (6/6)	100 (6/6)	100 (6/6)
	Verzenio	100 (3/3)	100 (3/3)	100 (3/3)
Ferrer	Xepi	100 (2/2)	100 (2/2)	100 (2/2)
Gilead	Epclusa	100 (9/9)	100 (9/9)	100 (9/9)
	Vosevi	88 (7/8)	100 (8/8)	88 (7/8)
Johnson & Johnson/Janssen	Tremfya	100 (5/5)	80 (4/5)	80 (4/5)
La Jolla	Giapreza	100 (1/1)	100 (1/1)	100 (1/1)
Lexicon	Xermelo	100 (4/4)	75 (3/4)	75 (3/4)
Lupin	Solosec	100 (3/3)	0 (0/3)	0 (0/3)
Melinta Therapeutics	Baxdela	50 (2/4)	50 (2/4)	25 (1/4)
Merck KGaA/EMD Serono	Bavencio	NA	NA	NA
Merck Sharp & Dohme	Prevymis	100 (2/2)	100 (2/2)	100 (2/2)
	Steglatro	100 (9/9)	100 (9/9)	100 (9/9)
	Zepatier	100 (14/14)	100 (14/14)	100 (14/14)
	Zinplava	100 (2/2)	100 (2/2)	100 (2/2)
Mitsubishi Tanabe	Radicava	NA	NA	NA
Neurocrine Biosciences	Ingrezza	100 (5/5)	80 (4/5)	80 (4/5)
Novartis	Erelzi	NA	NA	NA
	Kisqali	100 (1/1)	100 (1/1)	100 (1/1)
	Rydapt	100 (2/2)	100 (2/2)	100 (2/2)
Novo Nordisk	Macrilen	100 (2/2)	100 (2/2)	100 (2/2)
	Ozempic	100 (7/7)	86 (6/7)	86 (6/7)
Pfizer/Wyeth	Besponsa	100 (2/2)	100 (2/2)	100 (2/2)
Pfizer/Anacor	Eucrisa	80 (4/5)	80 (4/5)	80 (4/5)

Portola	Bevyxxa	100 (2/2)	100 (2/2)	100 (2/2)
PTC Therapeutics	Emflaza	50 (1/2)	0 (0/2)	0 (0/2)
Puma Biotechnology	Nerlynx	100 (5/5)	100 (5/5)	100 (5/5)
Radius	Tymlos	75 (3/4)	75 (3/4)	50 (2/4)
Regeneron	Dupixent	100 (8/8)	0 (0/8)	0 (0/8)
The Medicines Company/Rempex	Vabomere	100 (2/2)	50 (1/2)	50 (1/2)
Roche/Genentech	Hemlibra	100 (1/1)	100 (1/1)	100 (1/1)
	Ocrevus	100 (4/4)	100 (4/4)	100 (4/4)
	Tecentriq	100 (4/4)	100 (4/4)	100 (4/4)
Sanofi	Adlyxin	100 (14/14)	93 (13/14)	93 (13/14)
	Kevzara	100 (8/8)	100 (8/8)	100 (8/8)
Shionogi	Symproic	80 (4/5)	100 (5/5)	80 (4/5)
Shire/Baxalta	Cuvitru	100 (2/2)	50 (1/2)	50 (1/2)
Shire	Xiidra	100 (5/5)	100 (5/5)	100 (5/5)
Synergy	Trulance	100 (5/5)	0 (0/5)	0 (0/5)
Takeda/Ariad	Alunbrig	100 (2/2)	100 (2/2)	100 (2/2)
Tesaro	Zejula	100 (1/1)	0 (0/1)	0 (0/1)
Teva	Austedo	100 (2/2)	50 (1/2)	50 (1/2)
Ultragenyx	Mepsevii	100 (2/2)	100 (2/2)	100 (2/2)
US Worldmeds	Xadago	100 (3/3)	100 (3/3)	100 (3/3)
Valeant	Siliq	100 (4/4)	100 (4/4)	100 (4/4)
Median [IQR]		100 [100-100]	100 [75-100]	100 [66-100]
Percentage fully meeting measure		89 (49/55)	62 (34/55)	58 (32/55)

Supplement Table 4: Company and product characteristics

Company	Company size	Headquarter location (US vs non-US) ^a	Product brand name	Product type	FDA approval year	Approved indication (short form)
AbbVie	Large	US	Mavyret	Drug	2017	Hepatitis C viral infection
			Venclexta	Drug	2016	Relapsed or refractory chronic lymphocytic leukemia
Aerie	Non-large	US	Rhopressa	Drug	2017	Open-angle glaucoma, ocular hypertension
Amgen	Large	US	Amjevita	Biologic	2016	Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, ulcerative colitis
			Parsabiv	Drug	2017	Secondary hyperparathyroidism in chronic kidney disease
AstraZeneca	Large	Non-US	Calquence	Drug	2017	Mantle cell lymphoma
			Fasenra	Biologic	2017	Severe asthma
			Imfinzi	Biologic	2017	Metastatic urothelial carcinoma
			Vyzulta	Drug	2017	Open-angle glaucoma, ocular hypertension
Bayer	Large	Non-US	Aliqopa	Drug	2017	Relapsed follicular lymphoma
			Kovaltry	Biologic	2016	Hemophilia A
Biogen	Large	US	Spinraza	Drug	2016	Spinal muscular dystrophy
			Zinbryta	Biologic	2016	Prophylaxis of acute organ rejection in renal transplant
BioMarin	Non-large	US	Brineura	Biologic	2017	Late infantile neuronal ceroid lipofuscinosis Type 2
Celgene	Large	US	Idhifa	Drug	2017	Relapsed or refractory acute myeloid leukemia
Chemo Research	Non-large	Non-US	Benznidazole	Drug	2017	Chagas disease
Eli Lilly	Large	US	Lartruvo	Biologic	2016	Soft tissue sarcoma
			Taltz	Biologic	2016	Moderate-to-severe plaque psoriasis
			Verzenio	Drug	2017	HR+, HER2- advanced or metastatic breast cancer
Ferrer	Non-large	Non-US	Xepi	Drug	2017	Impetigo
Gilead	Large	US	Epclusa	Drug	2016	Chronic hepatitis C viral infection
			Vosevi	Drug	2017	Chronic hepatitis C viral infection
Johnson & Johnson/Janssen	Large	US	Tremfya	Biologic	2017	Moderate-to-severe plaque psoriasis
La Jolla	Non-large	US	Giapreza	Drug	2017	Septic or distributive shock
Lexicon	Non-large	US	Xermelo	Drug	2017	Carcinoid syndrome diarrhea
Lupin	Non-large	Non-US	Solosec	Drug	2017	Bacterial vaginosis
Melinta Therapeutics	Non-large	US	Baxdela	Drug	2017	Acute bacterial skin and skin structure infections
Merck KGaA/EMD Serono	Large	Non-US	Bavencio	Biologic	2017	Metastatic Merkel cell carcinoma
Merck Sharp & Dohme	Large	US	Prevymis	Drug	2017	Cytomegalovirus infection prophylaxis
			Steglatro	Drug	2017	Diabetes mellitus
			Zepatier	Drug	2016	Chronic hepatitis C viral infection
			Zinplava	Biologic	2016	Clostridium difficile infection
Mitsubishi Tanabe	Non-large	Non-US	Radicava	Drug	2017	Amyotrophic lateral sclerosis
Neurocrine Biosciences	Non-large	US	Ingrezza	Drug	2017	Tardive dyskinesia
Novartis	Large	Non-US	Erelzi	Biologic	2016	Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
			Kisqali	Drug	2017	HR+, HER2- advanced or metastatic breast cancer

			Rydapt	Drug	2017	Acute myeloid leukemia, aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia
Novo Nordisk	Large	Non-US	Macrilen	Drug	2017	Adult growth hormone deficiency
			Ozempic	Drug	2017	Type 2 diabetes mellitus
Pfizer/Wyeth	Large	US	Besponsa	Biologic	2017	Acute lymphoblastic leukemia
Pfizer/Anacor	Large	US	Eucrisa	Drug	2016	Mild-to-moderate atopic dermatitis
Portola	Non-large	US	Bevyxxa	Drug	2017	Venous thromboembolism prophylaxis
PTC Therapeutics	Non-large	US	Emflaza	Drug	2017	Duchenne muscular dystrophy
Puma Biotechnology	Non-large	US	Nerlynx	Drug	2017	Early stage HER2- breast cancer
Radius	Non-large	US	Tymlos	Drug	2017	Osteoporosis
Regeneron	Non-large	US	Dupixent	Biologic	2017	Moderate-to-severe atopic dermatitis
The Medicines Company/Rempex	Non-large	US	Vabomere	Drug	2017	Complicated urinary tract infection
Roche/Genentech	Large	Non-US	Hemlibra	Biologic	2017	Hemophilia A
			Ocrevus	Biologic	2017	Relapsing or primary progressive forms of multiple sclerosis
			Tecentriq	Biologic	2016	Metastatic urothelial carcinoma metastatic non-small cell lung cancer
Sanofi	Large	Non-US	Adlyxin	Biologic	2016	Type 2 diabetes mellitus
			Kevzara	Biologic	2017	Moderate-to-severe rheumatoid arthritis
Shionogi	Non-large	Non-US	Symproic	Drug	2017	Opioid induced constipation
Shire/Baxalta	Large	US	Cuvitru	Biologic	2016	Primary humoral immunodeficiency
Shire	Large	US	Xiidra	Drug	2016	Dry eye disease
Synergy	Large	US	Trulance	Drug	2017	Chronic idiopathic constipation
Takeda/Ariad	Non-large	Non-US	Alunbrig	Drug	2017	Non-small cell lung cancer
Tesaro	Non-large	US	Zejula	Drug	2017	Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Teva	Non-large	Non-US	Austedo	Drug	2017	Tardive dyskinesia and Huntington's disease chorea
Ultragenyx	Non-large	US	Mepsevii	Biologic	2017	Mucopolysaccharidosis type VII
US Worldmeds	Non-large	US	Xadago	Drug	2017	Parkinson's disease
Valeant	Non-large	Non-US	Siliq	Biologic	2017	Moderate-to-severe plaque psoriasis

^aParent company headquarter locations are indicated.